Truist Securities Maintains Buy on Elevance Health, Raises Price Target to $620
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald maintains a Buy rating on Elevance Health (NYSE:ELV) and raises the price target from $600 to $620.
July 15, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on Elevance Health and increased the price target from $600 to $620, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from a reputable analyst suggest positive sentiment and expected growth for Elevance Health, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100